Real Life Analysis Shows Regorafenib Improves Survival Upon Progression on Sorafenib in HCC скачать в хорошем качестве

Real Life Analysis Shows Regorafenib Improves Survival Upon Progression on Sorafenib in HCC

Maria Varela, of the Liver Unit at the Hospital Universitario Central de Asturias in Oviedo, Spain, discusses the findings from an analysis comparing the safety and efficacy of sorafenib (Nexavar) versus regorafenib (Stivarga) in a real-life cohort of patients with hepatocellular carcinoma (HCC) following progression). Patients that switched from sorafenib to regorafenib upon progression had an overall survival (OS) of 28 months compared to 8 months when they stayed on sorafenib, says Varela. However, these findings are from an observational study, as opposed to a randomized clinical trial with 2 cohorts of patients, where 1 cohort receives sorafenib then sorafenib upon progression and another that receives sorafenib then regorafenib upon progression. All patients in this study had the opportunity to move on to regorafenib, but if a patient presented with clinical progression or cirrhosis, they had to either stop therapy or continue with sorafenib. Only better candidates were able to move on to regorafenib, while other baseline conditions may have influenced the OS of 28 months as well, Varela concludes. For more resources and information regarding anticancer targeted therapies in liver cancer: https://www.targetedonc.com/resource-...